Introduction
Drugs and botanical dietary supplements can interact with some therapeutic agents by inhibiting or inducing drug metabolizing enzymes or drug transporters.
Inhibition of these enzymes and transporters can result in longer half-lives and higher and possibly toxic concentrations of therapeutic agents whereas induction can have the opposite effect. The most common form of drug-drug or drug-botanical interaction is inhibition of cytochrome P450 (CYP) enzymes. Examples include inhibition of CYP2D6 by paroxetine (Bertelsen et al., 2003) and inhibition of CYP3A4 by goldenseal (Hydrastis canadensis) (Chatterjee and Franklin, 2003; Gurley et al., 2005) .
In vitro CYP inhibition assays are widely used to study potential drug-drug and drug-botanical interactions. Although these assays typically evaluate inhibition of one CYP isoform at a time, the U.S. Food and Drug Administration (FDA) recommends that at least seven CYP isoforms should be investigated for possible inhibition by each new drug entity under development (Food and Drug Administration, 2012) . To expedite these assays, several cocktail approaches, also known as n-in-one assays, have been developed to test for inhibition of several CYP isoforms simultaneously. Most of these assays test for inhibition of five to eight CYP isoforms and use a wide variety of experimental conditions and probe substrates (Dierks et al., 2001 ; Testino and Patonay, D M D # 6 5 9 8 7 5 avoid CYP interactions before pooling the mixtures immediately prior to a quantitative analysis step, utilize CYP substrates which are not recommended by the FDA, and/or use long incubation times of up to 60 min (Kim et al., 2005; Turpeinen et al., 2005; Tolonen et al., 2007; Dinger et al., 2014) .
To address these assay limitations for the investigation of drug-drug interactions while including drug-botanical interactions which are important to our laboratory, we developed and validated a high-throughput CYP cocktail inhibition assay using 10 substrates against 9 CYP enzymes. Simultaneously assessing the inhibition of 9 CYP isoforms can significantly reduce the cost and time needed for the evaluation of drugdrug and drug-botanical interactions. Our in vitro high-throughput cocktail approach optimized enzyme protein concentration, minimized probe substrate interactions, minimized solvent effects, and utilized a fast and sensitive UHPLC-MS/MS quantitative assay (Chauret et al., 1998; Busby et al., 1999; Yuan et al., 2002; Turpeinen et al., 2005;  D M D # 6 5 9 8 7 6 2. Materials and Methods
Materials and Chemicals
Phenacetin was purchased from Tokyo Chemical Industry (Tokyo, Japan).
Acetaminophen, coumarin, bupropion hydrochloride, tolbutamide, dextrorphan tartrate, chlorzoxazone, 6β-hydroxytestosterone, furafylline, ticlopidine hydrochloride, quercetin, The licorice root was extracted with 90% ethanol, 5% isopropanol, 5% water (v/v/v) (weight root powder (g)/volume solvent (mL): 1:15).
Microsomal Incubations
Potassium phosphate buffer (100 µL, 0.1 M, pH 7.4) containing 1.3 mM NADPH, 0.2 mg/mL human liver microsomes, and a cocktail of 10 probe substrates (phenacetin for CYP1A2, coumarin for CYP2A6, bupropion for CYP2B6, amodiaquine for CYP2C8, tolbutamide for CYP2C9, (S)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6, chlorzoxazone for CYP2E1, and midazolam and testosterone for CYP3A4/5) ( Table 1 ) or a single substrate (around K m ) were incubated at 37 °C for 10 min.
Methanol was used to dissolve the substrate cocktail or individual substrate and comprised <0.3% (v/v) of the total incubation mixture. The reactions were terminated by adding 20 µL of a stop solution consisting of water/acetonitrile/formic acid, (92:5:3; v/v/v) containing stable isotope-labeled surrogate standards ( Table 1) . The samples were then centrifuged at 13000 x g at 4 °C for 15 min prior to analysis using UHPLC-MS/MS. 
UHPLC-MS/MS
All metabolites and surrogate standards were analyzed in a single run using 
Results
The ten probe substrates specific to 9 CYP isoforms ( 
Probe Substrate Selection and Mass Spectrometry
Phenacetin O-deethylation by CYP1A2 was selected for the cocktail assay and is often used in other cocktails (Yuan et al., 2002; Spaggiari et al., 2014) because of its superior specificity compared to other FDA-recommended substrates. Among several possible probes for CYP2A6, CYP2B6 and CYP2E1, coumarin-7-hydroxyation, bupropion-hydroxylation and chlorzoxazone 6-hydroxylation were selected based on the commercial availability of the corresponding stable isotope-labeled metabolites for use as surrogate standards during UHPLC-MS/MS (Figure 1 ). For CYP2C8, taxol and amodiaquine are frequently used as probe substrates, however, the higher solubility of amodiaquine makes it superior for cocktail applications (Spaggiari et al., 2014) .
Therefore, amodiaquine N-deethylation by CYP2C8 was measured instead of taxol hydroxylation.
Tolbutamide and diclofenac are frequently used as probe substrates for CYP2C9, and bufuralol and dextromethorphan are often used as substrates of CYP2D6. Although either probe substrate of each pair could have been used in our assay, tolbutamide methyl-hydroxylation and dextromethorphan O-demethylation were used to measure interactions with CYP2C9 and CYP2D6, respectively. As a probe for CYP2C19, Smephenytoin 4'-hydroxylation is highly specific, however, cocktail assays typically use the less specific omeprazole due to the sensitivity limitations of most detection methods (Yuan et al., 2002; Testino and Patonay, 2003; Spaggiari et al., 2014) . Here, we were able to use the preferred probe substrate, (S)-mephenytoin, due to the high sensitivity of Chlorzoxazone was included in our cocktail assay as a probe for CYP2E1 (Figure 1) , because the fast polarity-switching and high sensitivity of this generation triple quadrupole mass spectrometer enabled the measurement of all ten probes including 6-hydroxychlorzoxazone and their surrogate standards in a single analysis.
Optimization of Probe Substrate Concentrations and Incubation Conditions
The probe substrate concentrations in cocktail assays should be probed. To be certain that appropriate concentrations of each probe substrate were utilized in our application, we determined the K m values for each probe substrate using the same experimental procedures, and the same batch of pooled human liver microsomes was used for all subsequent inhibition experiments ( Table 1) .
Possible interactions between the probe substrates of the CYP enzymes were evaluated, and substrate concentrations for the cocktail assay were adjusted to minimize these interactions. Phenacetin weakly inhibited CYP2B6 and CYP3A4/5 After optimizing the substrate concentrations for the cocktail assay (Table 1) , the linearity of metabolite formation was investigated. All 10 substrates were evaluated, 6 of them showed linearity up to 20 min, while 4 substrates were linear for 15 min or less (Figure 2) . Although a 10-min incubation time was not optimal for midazolam, it was the minimum required to ensure sufficient metabolite formation for the low-turnover substrates. Under these conditions, the inhibition potency of moderate inhibitors for midazolam 1-hydroxlyation might be underestimated (Ogilivie et al., 2008) . Therefore, further studies on any compounds/extracts that show moderate/weak inhibition of CYP3A4/5 (midazolam) would be recommended.
Validation and Application of the Cocktail Assay
Ideally, the cocktail cytochrome P450 enzyme inhibition assay should yield the same results as would be obtained if each substrate were assayed separately. As quantitative measures of the potencies of enzyme inhibitors, the IC 50 values for inhibitors tested individually or in the cocktail assay should also be comparable (Sittampalam GS, Gal-Edd N, Arkin M, 2004; Davis and Ward, 2014) . The ratios of the IC 50 values obtained using both approaches (Table 2 ) were compared and had ratios ranging from 1.03 to 1.82. Because these values were within a 2-fold range of each other, they were in good agreement. As additional validation of the cocktail method, the measured IC 50 values were consistent with values in the literature ( Table 2 ) (Eagling et al., 1998; Shader et al., 1999; Dierks et al., 2001; Giancarlo et al., 2001 ; Testino and , 2003; Patki et al., 2003; Walsky and Obach, 2004; Turpeinen et al., 2005; Kim et al., 2005; Workman and Raynaud, 2007; Zientek et al., 2008; Otten et al., 2011; Yao et al., 2012; Kozakai et al., 2012; Qin et al., 2014; Qiao et al., 2014; Liu et al., 2015) . In conclusion, an in vitro high-throughput cytochrome P450 cocktail inhibition assay containing 10 substrates for 9 CYP isoforms was developed using UHPLC-MS/MS and validated using known inhibitors of each CYP enzyme. This assay includes all 7 cytochrome P450 enzymes recommended for testing by the U.S. FDA as well as two additional isoforms, CYP2A6 and CYP2E1, which are also important in the metabolism of xenobiotic compounds such as nicotine (CYP2A6) et al., 1998; Testino and Patonay, 2003; Walsky and Obach, 2004; Zientek et al., 2008; Otten et al., 2011; Kozakai et al., 2012; Liu et al., 2015 et al., 2001; Walsky and Obach, 2004; Otten et al., 2011; Liu et al., 2015) CYP2C9 tolbutamide sulfaphenazole 0.53 ± 0.06 0.90 ± 0.10 0.069-1.30 (Eagling et al., 1998; Shader et al., 1999; Testino and Patonay, 2003; Workman and Raynaud, 2007; Zientek et al., 2008; Otten et al., 2011; Kozakai et al., 2012; Yao et al., 2012 86-4.46 (Giancarlo et al., 2001; Zientek et al., 2008; Yao et al., 2012; Qin et al., 2014; Liu et al., 2015) CYP2D6 dextromethorphan quinidine 0.46 ± 0.02 0.84 ± 0.10 0.009-0.52 (Shader et al., 1999; Testino and Patonay, 2003; Walsky and Obach, 2004; Zientek et al., 2008; Otten et al., 2011; Kozakai et al., 2012; Yao et al., 2012; Qiao et al., 2014; Qin et al., 2014; Liu et al., 2015) CYP3A4/5 midazolam ketoconazole 0.094 ± 0.006 0.115 ± 0.056 0.01-0.13 (Patki et al., 2003; Walsky and Obach, 2004; Workman and Raynaud, 2007; Otten et al., 2011; Kozakai et al., 2012; Yao et al., 2012; Qiao et al., 2014; Qin et al., 2014; Liu et al., 2015) testosterone 0.062 ± 0.004 0.054 ± 0.002 0.008-0.0477 (Eagling et al., 1998; Patki et al., 2003; Walsky and Obach, 2004; Kozakai et al., 2012; Yao et al., 2012; Qiao et al., 2014) CYP2E1 chlorzoxazone diethyldithiocarbamate 12.42 ± 1.70 22.58 ± 5.60
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